Buscar
Cingulate Inc
CINGAñadir a la lista de seguimiento
5.449USD
-0.441-7.48%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
64.89MCap. mercado
PérdidaP/E TTM
Más Datos de Cingulate Inc Compañía
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Información de Cingulate Inc
Símbolo de cotizaciónCING
Nombre de la empresaCingulate Inc
Fecha de salida a bolsaOct 07, 2021
Director ejecutivoCallahan (Jennifer L)
Número de empleados13
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 07
Dirección1901 W. 47Th Place
CiudadKANSAS CITY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal66205
Teléfono19139422300
Sitio Webhttps://www.cingulate.com/
Símbolo de cotizaciónCING
Fecha de salida a bolsaOct 07, 2021
Director ejecutivoCallahan (Jennifer L)
Ejecutivos de Cingulate Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Dr. Matthew N. (Matt) Brams, M.D.
Dr. Matthew N. (Matt) Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Nilay Patel, J.D.
Mr. Nilay Patel, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Dr. Matthew N. (Matt) Brams, M.D.
Dr. Matthew N. (Matt) Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Cingulate Inc?
Los cinco principales accionistas de Cingulate Inc son: Mr. Peter J. Werth
¿Cuántas instituciones poseen acciones de Cingulate Inc (CING)?
A fecha de 2026Q1, 38 instituciones poseen acciones de Cingulate Inc, con un valor de mercado combinado de aproximadamente 556.12K, lo que representa el 4.54% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -23762.00.